Seeking Alpha

SciClone Pharmaceuticals (SCLN +16.8%) are soaring after its Q2 bottom line topped Street...

SciClone Pharmaceuticals (SCLN +16.8%) are soaring after its Q2 bottom line topped Street estimates late yesterday. Total revenue jumped 22% Y/Y, helped by a 27% increase in sales of its drug Zadaxin, plus revenue growth from its primary care and oncology businesses in China and positive synergies from its recent takeover of NovaMed Pharmaceuticals.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|